Treatment Principles​

Presentation

Treatment Principles​

1 / 8
Treatment Principles​
1 / 8
Treatment goals in AD​
1 / 8
Treatment goals​
References
  1. Geldmacher DS, Frolich L, Doody RS, et al. Realistic expectations for treatment success in Alzheimer’s disease. J Nutr Health Aging 2006; 10 (5): 417–429.​
  2. Winblad B, Amouyel P, Andrieu S, et al. Defeating Alzheimer’s disease and other dementias: a priority for European science and society. Lancet Neurol 2016; 15 (5): 455–532.​
1 / 8
Treatment goals​
References
  1. Geldmacher DS, Frolich L, Doody RS, et al. Realistic expectations for treatment success in Alzheimer’s disease. J Nutr Health Aging 2006; 10 (5): 417–429.​
  2. Winblad B, Amouyel P, Andrieu S, et al. Defeating Alzheimer’s disease and other dementias: a priority for European science and society. Lancet Neurol 2016; 15 (5): 455–532.​
1 / 8
Treatment goals​
References
  1. Geldmacher DS, Frolich L, Doody RS, et al. Realistic expectations for treatment success in Alzheimer’s disease. J Nutr Health Aging 2006; 10 (5): 417–429.​
  2. Winblad B, Amouyel P, Andrieu S, et al. Defeating Alzheimer’s disease and other dementias: a priority for European science and society. Lancet Neurol 2016; 15 (5): 455–532.​
1 / 8
Treatment goals​
References
  1. Geldmacher DS, Frolich L, Doody RS, et al. Realistic expectations for treatment success in Alzheimer’s disease. J Nutr Health Aging 2006; 10 (5): 417–429.​
  2. Winblad B, Amouyel P, Andrieu S, et al. Defeating Alzheimer’s disease and other dementias: a priority for European science and society. Lancet Neurol 2016; 15 (5): 455–532.​
1 / 8
Treatment goals​
References
  1. Geldmacher DS, Frolich L, Doody RS, et al. Realistic expectations for treatment success in Alzheimer’s disease. J Nutr Health Aging 2006; 10 (5): 417–429.​
  2. Winblad B, Amouyel P, Andrieu S, et al. Defeating Alzheimer’s disease and other dementias: a priority for European science and society. Lancet Neurol 2016; 15 (5): 455–532.​
1 / 8
Treatment goals​
References
  1. Geldmacher DS, Frolich L, Doody RS, et al. Realistic expectations for treatment success in Alzheimer’s disease. J Nutr Health Aging 2006; 10 (5): 417–429.​
  2. Winblad B, Amouyel P, Andrieu S, et al. Defeating Alzheimer’s disease and other dementias: a priority for European science and society. Lancet Neurol 2016; 15 (5): 455–532.​
1 / 8
Symptomatic and disease-modifying treatments​
References
  1. Kennedy GJ. From symptom palliation to disease modification: implications for dementia care. Primary Psychiatry 2013. http://primarypsychiatry.com/from-symptom-palliation-to-disease-modifica.... Accessed 26 August 2016.​
  2. Van Dam D, De Deyn PP. Drug discovery in dementia: the role of rodent models. Nat Rev Drug Discov 2006; 5 (11): 956–970.​
  3. Winblad B, Amouyel P, Andrieu S, et al. Defeating Alzheimer’s disease and other dementias: a priority for European science and society. Lancet Neurol 2016; 15 (5): 455–532.
1 / 8
Symptomatic and disease-modifying treatments​
References
  1. Kennedy GJ. From symptom palliation to disease modification: implications for dementia care. Primary Psychiatry 2013. http://primarypsychiatry.com/from-symptom-palliation-to-disease-modifica.... Accessed 26 August 2016.​
  2. Van Dam D, De Deyn PP. Drug discovery in dementia: the role of rodent models. Nat Rev Drug Discov 2006; 5 (11): 956–970.​
  3. Winblad B, Amouyel P, Andrieu S, et al. Defeating Alzheimer’s disease and other dementias: a priority for European science and society. Lancet Neurol 2016; 15 (5): 455–532.
1 / 8
Symptomatic and disease-modifying treatments​
References
  1. Kennedy GJ. From symptom palliation to disease modification: implications for dementia care. Primary Psychiatry 2013. http://primarypsychiatry.com/from-symptom-palliation-to-disease-modifica.... Accessed 26 August 2016.​
  2. Van Dam D, De Deyn PP. Drug discovery in dementia: the role of rodent models. Nat Rev Drug Discov 2006; 5 (11): 956–970.​
  3. Winblad B, Amouyel P, Andrieu S, et al. Defeating Alzheimer’s disease and other dementias: a priority for European science and society. Lancet Neurol 2016; 15 (5): 455–532.
1 / 8
Symptomatic and disease-modifying treatments​
References
  1. Kennedy GJ. From symptom palliation to disease modification: implications for dementia care. Primary Psychiatry 2013. http://primarypsychiatry.com/from-symptom-palliation-to-disease-modifica.... Accessed 26 August 2016.​
  2. Van Dam D, De Deyn PP. Drug discovery in dementia: the role of rodent models. Nat Rev Drug Discov 2006; 5 (11): 956–970.​
  3. Winblad B, Amouyel P, Andrieu S, et al. Defeating Alzheimer’s disease and other dementias: a priority for European science and society. Lancet Neurol 2016; 15 (5): 455–532.
1 / 8
Symptomatic and disease-modifying treatments​
References
  1. Kennedy GJ. From symptom palliation to disease modification: implications for dementia care. Primary Psychiatry 2013. http://primarypsychiatry.com/from-symptom-palliation-to-disease-modification-implications-for-dementia-care/. Accessed 26 August 2016.​
  2. Van Dam D, De Deyn PP. Drug discovery in dementia: the role of rodent models. Nat Rev Drug Discov 2006; 5 (11): 956–970.​
  3. Winblad B, Amouyel P, Andrieu S, et al. Defeating Alzheimer’s disease and other dementias: a priority for European science and society. Lancet Neurol 2016; 15 (5): 455–532.
1 / 8
Key points​
1 / 8
Current approaches to AD management​
1 / 8
Current approaches to AD management​
References
  1. American Psychiatric Association; Rabins PV, Rovner BW, Rummans T, et al. Guideline watch for the practice guideline for the treatment of patients with Alzheimer’s disease and other dementias. October 2014.​
  2. APA Work Group on Alzheimer’s Disease and other Dementias, Rabins PV, Blacker D, Rovner BW, et al.; Steering Committee on Practice Guidelines, McIntyre JS, Charles SC, Anzia DJ, et al. American Psychiatric Association practice guideline for the treatment of patients with Alzheimer’s disease and other dementias, 2nd edition. Am J Psychiatry 2007; 164 (12 Suppl): 5–56.​
1 / 8
Current approaches to AD management​
References
  1. American Psychiatric Association; Rabins PV, Rovner BW, Rummans T, et al. Guideline watch for the practice guideline for the treatment of patients with Alzheimer’s disease and other dementias. October 2014.​
  2. APA Work Group on Alzheimer’s Disease and other Dementias, Rabins PV, Blacker D, Rovner BW, et al.; Steering Committee on Practice Guidelines, McIntyre JS, Charles SC, Anzia DJ, et al. American Psychiatric Association practice guideline for the treatment of patients with Alzheimer’s disease and other dementias, 2nd edition. Am J Psychiatry 2007; 164 (12 Suppl): 5–56.​
1 / 8
Current approaches to AD management​
References
  1. American Psychiatric Association; Rabins PV, Rovner BW, Rummans T, et al. Guideline watch for the practice guideline for the treatment of patients with Alzheimer’s disease and other dementias. October 2014.​
  2. APA Work Group on Alzheimer’s Disease and other Dementias, Rabins PV, Blacker D, Rovner BW, et al.; Steering Committee on Practice Guidelines, McIntyre JS, Charles SC, Anzia DJ, et al. American Psychiatric Association practice guideline for the treatment of patients with Alzheimer’s disease and other dementias, 2nd edition. Am J Psychiatry 2007; 164 (12 Suppl): 5–56.​
1 / 8
Current approaches to AD management​
References
  1. American Psychiatric Association; Rabins PV, Rovner BW, Rummans T, et al. Guideline watch for the practice guideline for the treatment of patients with Alzheimer’s disease and other dementias. October 2014.​
  2. APA Work Group on Alzheimer’s Disease and other Dementias, Rabins PV, Blacker D, Rovner BW, et al.; Steering Committee on Practice Guidelines, McIntyre JS, Charles SC, Anzia DJ, et al. American Psychiatric Association practice guideline for the treatment of patients with Alzheimer’s disease and other dementias, 2nd edition. Am J Psychiatry 2007; 164 (12 Suppl): 5–56.​
1 / 8
Current approaches to AD management​
References
  1. American Psychiatric Association; Rabins PV, Rovner BW, Rummans T, et al. Guideline watch for the practice guideline for the treatment of patients with Alzheimer’s disease and other dementias. October 2014.​
  2. APA Work Group on Alzheimer’s Disease and other Dementias, Rabins PV, Blacker D, Rovner BW, et al.; Steering Committee on Practice Guidelines, McIntyre JS, Charles SC, Anzia DJ, et al. American Psychiatric Association practice guideline for the treatment of patients with Alzheimer’s disease and other dementias, 2nd edition. Am J Psychiatry 2007; 164 (12 Suppl): 5–56.​
1 / 8
Psychosocial therapies for AD​
References
  1. American Psychiatric Association; Rabins PV, Rovner BW, Rummans T, et al. Guideline watch for the practice guideline for the treatment of patients with Alzheimer’s disease and other dementias. October 2014.​
  2. APA Work Group on Alzheimer’s Disease and other Dementias, Rabins PV, Blacker D, Rovner BW, et al.; Steering Committee on Practice Guidelines, McIntyre JS, Charles SC, Anzia DJ, et al. American Psychiatric Association practice guideline for the treatment of patients with Alzheimer’s disease and other dementias, 2nd edition. Am J Psychiatry 2007; 164 (12 Suppl): 5–56.​
1 / 8
Psychosocial therapies for AD​
References
  1. American Psychiatric Association; Rabins PV, Rovner BW, Rummans T, et al. Guideline watch for the practice guideline for the treatment of patients with Alzheimer’s disease and other dementias. October 2014.​
  2. APA Work Group on Alzheimer’s Disease and other Dementias, Rabins PV, Blacker D, Rovner BW, et al.; Steering Committee on Practice Guidelines, McIntyre JS, Charles SC, Anzia DJ, et al. American Psychiatric Association practice guideline for the treatment of patients with Alzheimer’s disease and other dementias, 2nd edition. Am J Psychiatry 2007; 164 (12 Suppl): 5–56.​
1 / 8
Psychosocial therapies for AD​
References
  1. American Psychiatric Association; Rabins PV, Rovner BW, Rummans T, et al. Guideline watch for the practice guideline for the treatment of patients with Alzheimer’s disease and other dementias. October 2014.​
  2. APA Work Group on Alzheimer’s Disease and other Dementias, Rabins PV, Blacker D, Rovner BW, et al.; Steering Committee on Practice Guidelines, McIntyre JS, Charles SC, Anzia DJ, et al. American Psychiatric Association practice guideline for the treatment of patients with Alzheimer’s disease and other dementias, 2nd edition. Am J Psychiatry 2007; 164 (12 Suppl): 5–56.​
1 / 8
Psychosocial therapies for AD​
References
  1. American Psychiatric Association; Rabins PV, Rovner BW, Rummans T, et al. Guideline watch for the practice guideline for the treatment of patients with Alzheimer’s disease and other dementias. October 2014.​
  2. APA Work Group on Alzheimer’s Disease and other Dementias, Rabins PV, Blacker D, Rovner BW, et al.; Steering Committee on Practice Guidelines, McIntyre JS, Charles SC, Anzia DJ, et al. American Psychiatric Association practice guideline for the treatment of patients with Alzheimer’s disease and other dementias, 2nd edition. Am J Psychiatry 2007; 164 (12 Suppl): 5–56.​
1 / 8
Psychosocial therapies for AD​
References
  1. American Psychiatric Association; Rabins PV, Rovner BW, Rummans T, et al. Guideline watch for the practice guideline for the treatment of patients with Alzheimer’s disease and other dementias. October 2014.​
  2. APA Work Group on Alzheimer’s Disease and other Dementias, Rabins PV, Blacker D, Rovner BW, et al.; Steering Committee on Practice Guidelines, McIntyre JS, Charles SC, Anzia DJ, et al. American Psychiatric Association practice guideline for the treatment of patients with Alzheimer’s disease and other dementias, 2nd edition. Am J Psychiatry 2007; 164 (12 Suppl): 5–56.​
1 / 8
Psychosocial therapies for AD​
References
  1. American Psychiatric Association; Rabins PV, Rovner BW, Rummans T, et al. Guideline watch for the practice guideline for the treatment of patients with Alzheimer’s disease and other dementias. October 2014.​
  2. APA Work Group on Alzheimer’s Disease and other Dementias, Rabins PV, Blacker D, Rovner BW, et al.; Steering Committee on Practice Guidelines, McIntyre JS, Charles SC, Anzia DJ, et al. American Psychiatric Association practice guideline for the treatment of patients with Alzheimer’s disease and other dementias, 2nd edition. Am J Psychiatry 2007; 164 (12 Suppl): 5–56.​
1 / 8
Psychosocial therapies for AD​
References
  1. American Psychiatric Association; Rabins PV, Rovner BW, Rummans T, et al. Guideline watch for the practice guideline for the treatment of patients with Alzheimer’s disease and other dementias. October 2014.​
  2. APA Work Group on Alzheimer’s Disease and other Dementias, Rabins PV, Blacker D, Rovner BW, et al.; Steering Committee on Practice Guidelines, McIntyre JS, Charles SC, Anzia DJ, et al. American Psychiatric Association practice guideline for the treatment of patients with Alzheimer’s disease and other dementias, 2nd edition. Am J Psychiatry 2007; 164 (12 Suppl): 5–56.​
1 / 8
Disease-stage-specific treatment​
References
  1. APA Work Group on Alzheimer’s Disease and other Dementias, Rabins PV, Blacker D, Rovner BW, et al.; Steering Committee on Practice Guidelines, McIntyre JS, Charles SC, Anzia DJ, et al. American Psychiatric Association practice guideline for the treatment of patients with Alzheimer’s disease and other dementias, 2nd edition. Am J Psychiatry 2007; 164 (12 Suppl): 5–56.​
  2. American Psychiatric Association; Rabins PV, Rovner BW, Rummans T, et al. Guideline watch for the practice guideline for the treatment of patients with Alzheimer’s disease and other dementias. October 2014.​
  3. Geldmacher DS, Frolich L, Doody RS, et al. Realistic expectations for treatment success in Alzheimer’s disease. J Nutr Health Aging 2006; 10 (5): 417–429.​
  4. Grossberg GT, Desai AK. Management of Alzheimer’s disease. J Gerontol A Biol Sci Med Sci 2003; 58 (4): 331–353.​
  5. Schmidt R, Hofer E, Bouwman FH, et al. EFNS-ENS/EAN Guideline on concomitant use of cholinesterase inhibitors and memantine in moderate to severe Alzheimer’s disease. Eur J Neurol 2015; 22 (6): 889–898.​​
1 / 8
Disease-stage-specific treatment​
References
  1. APA Work Group on Alzheimer’s Disease and other Dementias, Rabins PV, Blacker D, Rovner BW, et al.; Steering Committee on Practice Guidelines, McIntyre JS, Charles SC, Anzia DJ, et al. American Psychiatric Association practice guideline for the treatment of patients with Alzheimer’s disease and other dementias, 2nd edition. Am J Psychiatry 2007; 164 (12 Suppl): 5–56.​
  2. American Psychiatric Association; Rabins PV, Rovner BW, Rummans T, et al. Guideline watch for the practice guideline for the treatment of patients with Alzheimer’s disease and other dementias. October 2014.​
  3. Geldmacher DS, Frolich L, Doody RS, et al. Realistic expectations for treatment success in Alzheimer’s disease. J Nutr Health Aging 2006; 10 (5): 417–429.​
  4. Grossberg GT, Desai AK. Management of Alzheimer’s disease. J Gerontol A Biol Sci Med Sci 2003; 58 (4): 331–353.​
  5. Schmidt R, Hofer E, Bouwman FH, et al. EFNS-ENS/EAN Guideline on concomitant use of cholinesterase inhibitors and memantine in moderate to severe Alzheimer’s disease. Eur J Neurol 2015; 22 (6): 889–898.​
1 / 8
Disease-stage-specific treatment​
References
  1. APA Work Group on Alzheimer’s Disease and other Dementias, Rabins PV, Blacker D, Rovner BW, et al.; Steering Committee on Practice Guidelines, McIntyre JS, Charles SC, Anzia DJ, et al. American Psychiatric Association practice guideline for the treatment of patients with Alzheimer’s disease and other dementias, 2nd edition. Am J Psychiatry 2007; 164 (12 Suppl): 5–56.​
  2. American Psychiatric Association; Rabins PV, Rovner BW, Rummans T, et al. Guideline watch for the practice guideline for the treatment of patients with Alzheimer’s disease and other dementias. October 2014.​
  3. Geldmacher DS, Frolich L, Doody RS, et al. Realistic expectations for treatment success in Alzheimer’s disease. J Nutr Health Aging 2006; 10 (5): 417–429.​
  4. Grossberg GT, Desai AK. Management of Alzheimer’s disease. J Gerontol A Biol Sci Med Sci 2003; 58 (4): 331–353.​
  5. Schmidt R, Hofer E, Bouwman FH, et al. EFNS-ENS/EAN Guideline on concomitant use of cholinesterase inhibitors and memantine in moderate to severe Alzheimer’s disease. Eur J Neurol 2015; 22 (6): 889–898.​
1 / 8
Disease-stage-specific treatment​
References
  1. APA Work Group on Alzheimer’s Disease and other Dementias, Rabins PV, Blacker D, Rovner BW, et al.; Steering Committee on Practice Guidelines, McIntyre JS, Charles SC, Anzia DJ, et al. American Psychiatric Association practice guideline for the treatment of patients with Alzheimer’s disease and other dementias, 2nd edition. Am J Psychiatry 2007; 164 (12 Suppl): 5–56.​
  2. American Psychiatric Association; Rabins PV, Rovner BW, Rummans T, et al. Guideline watch for the practice guideline for the treatment of patients with Alzheimer’s disease and other dementias. October 2014.​
  3. Geldmacher DS, Frolich L, Doody RS, et al. Realistic expectations for treatment success in Alzheimer’s disease. J Nutr Health Aging 2006; 10 (5): 417–429.​
  4. Grossberg GT, Desai AK. Management of Alzheimer’s disease. J Gerontol A Biol Sci Med Sci 2003; 58 (4): 331–353.​
  5. Schmidt R, Hofer E, Bouwman FH, et al. EFNS-ENS/EAN Guideline on concomitant use of cholinesterase inhibitors and memantine in moderate to severe Alzheimer’s disease. Eur J Neurol 2015; 22 (6): 889–898.
1 / 8
Key points​
Country selection
We are registering that you are located in Brazil - if that's correct then please continue to Progress in Mind Brazil
You are leaving Progress in Mind